clinical_trials
Novel ADC Achieves Impressive PFS Advantage in HER2-Low Metastatic Breast Cancer
Confidence86·multiple reportsImportance88NP-EVT-20261024-E755CC4
(MedPage Today) -- Patients with recurrent or metastatic HER2-low breast cancer had dramatic improvement in progression-free survival (PFS) when treated with a novel antibody-drug conjugate (ADC) targeting HER2, a large randomized trial showed...
Read the original at the primary source
Novel ADC Achieves Impressive PFS Advantage in HER2-Low Metastatic Breast Cancer
10/24/2026, 9:02:29 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —